Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Identify Predictors of Clinical Outcomes in Real-world Patients With HR+ and HER2-low/Negative Breast Cancer Treated With Neoadjuvant Chemotherapy or Endocrine Therapy

NCT06040593 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT06040593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06040593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Identify Predictors of Clinical Outcomes in Real-world Patients With HR+ and HER2-low/Negative Breast Cancer Treated With Neoadjuvant Chemotherapy or Endocrine Therapy
Lead sponsor
Daiichi Sankyo
Phase
Observational
Overall status
Completed
Start date
July 31, 2023
Completion date
February 23, 2024
Enrollment
927 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-low breast cancer, her2-negative breast cancer, hormone-receptor-positive breast cancer